Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 12/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | HTR7 | P34969 | 1/20 | 0.69 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15679325 | 0.83 | TAAR1 (0.78) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903735 | 0.83 | TAAR1 (0.74) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903742 | 0.83 | TAAR1 (0.74) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903741 | 0.83 | TAAR1 (0.74) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL28945875 | 0.83 | TAAR1 (0.77) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903730 | 0.83 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903739 | 0.83 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL12644088 | 0.83 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL2084075 | 0.82 | TAAR1 (0.47) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL14903737 | 0.82 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402937-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20210053983-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10815249-B2 | Salts, crystal forms, and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190256525-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815249-B2 | Salts, crystal forms, and production methods thereof | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-20220402937-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-20190256525-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
| US-20210053983-A1 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | TPMT, HNMT, NT5C3B | TAAR1 847/4885HTR1A 121/4885DRD2 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.